Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 118

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 118
---
, Kadimastem’s directors and executive officers as a group, owned and were entitled to vote 1,761,141 Kadimastem Ordinary Shares on a fully diluted basis, or 24.65% of the outstanding Kadimastem Ordinary Shares on a fully diluted basis. The Merger has been approved by the shareholders of Kadimastem. Termination of the Merger Agreement (Page 161) The Merger Agreement contains customary termination rights for each of NLS and Kadimastem, including the right of NLS and Kadimastem to terminate the Merger Agreement if the Closing shall not have occurred on or before August31, 2025, which outside date can be extended by mutual agreement. The Merger Agreement also provides that NLS shall pay to Kadimastem a termination fee of $10,000,000 plus the NLS Operating Expenses (as defined in the Merger Agreement), up to a maximum of $250,000 per month beginning July 28, 2024, and the Transaction Expenses (as defined in the Merger Agreement) if NLS terminates the Merger Agreement prior to obtaining the Parent Requisite Vote (as defined in the Merger Agreement) to enter into a definitive agreement providing for a Parent Superior Proposal (as defined in the Merger Agreement) in accordance with terms of the Merger Agreement. Related Agreements (Page 163) Contingent Value Right Agreement Prior to the Closing, NLS will enter into the CVR Agreement with VStock Transfer, LLC, or the Rights Agent, which will govern the terms of the CVRs. Each CVR will represent the right to additional payments based on the proceeds, subject to certain adjustments, received by NLS from the disposition of the Legacy Assets. The right to the CVRs as evidenced by the CVR Agreement is a contractual right only and will not be transferable, except in the limited circumstances specified in the CVR Agreement. Support Agreements Concurrently with the execution of the Merger Agreement, NLS entered into Support Agreement with the Supporting Persons, covering approximately 40% of the outstanding NLS Common Shares. Pursuant to the Support Agreements, each Supporting Person has agreed, among other things, to vote its NLS Common Shares, and any other voting securities such Supporting Person might hold, in favor of (A) (i) the issuance of NLS Common Shares equal to the required number of NLS Common Shares to serve as the Merger Consideration, and (ii)